A 65-year-old man with advanced HCC has Child-Pugh B7 cirrhosis. He asks about systemic therapy. Most HCC trials enrolled Child-Pugh A patients. What

Question

A 65-year-old man with advanced HCC has Child-Pugh B7 cirrhosis. He asks about systemic therapy. Most HCC trials enrolled Child-Pugh A patients. What limited evidence exists for treating Child-Pugh B7?

Accepted Answer

Limited real-world data suggest selected Child-Pugh B7 patients may tolerate atezolizumab + bevacizumab or TKIs with close monitoring

Answer

Liver transplant is the only option as the preferred next management strategy at this stage in the clinical context described

Answer

Only sorafenib is safe in Child-Pugh B as the preferred next management strategy at this stage in the clinical context described

Answer

All Child-Pugh B patients tolerate treatment identically to A as the preferred next management strategy in this patient

Answer

No evidence as the preferred next management strategy at this stage in the clinical context described

HCC Child-Pugh B7 — SCE Medical Oncology MCQ

A 65-year-old man with advanced HCC has Child-Pugh B7 cirrhosis. He asks about systemic therapy. Most HCC trials enrolled Child-Pugh A patients. What limited evidence exists for treating Child-Pugh B7?